SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

Search

Vetoquinol SA

Chiusa

SettoreSettore sanitario

81.2 1.88

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

80.9

Massimo

81.4

Metriche Chiave

By Trading Economics

Entrata

25M

Vendite

10M

268M

P/E

Media del settore

16.471

60.328

Rendimento da dividendi

1.16

Margine di Profitto

9.734

Dipendenti

2,497

EBITDA

252M

301M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+34.31% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.16%

2.24%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

59M

994M

Apertura precedente

79.32

Chiusura precedente

81.2

Notizie sul Sentiment di mercato

By Acuity

50%

50%

155 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Vetoquinol SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 apr 2026, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Utili

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Utili

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Utili

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisizioni, Fusioni, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Discorsi di Mercato

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Discorsi di Mercato

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Utili

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Utili

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Discorsi di Mercato

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Discorsi di Mercato

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Discorsi di Mercato
Utili

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Vetoquinol SA Previsione

Obiettivo di Prezzo

By TipRanks

34.31% in crescita

Previsioni per 12 mesi

Media 110 EUR  34.31%

Alto 110 EUR

Basso 110 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Vetoquinol SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

72.6 / 75.1Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

155 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat